Compare CVCO & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVCO | LGND |
|---|---|---|
| Founded | 1965 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | CVCO | LGND |
|---|---|---|
| Price | $597.07 | $189.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $550.00 | $144.71 |
| AVG Volume (30 Days) | ★ 147.8K | 139.7K |
| Earning Date | 01-29-2026 | 08-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.54 | N/A |
| EPS | ★ 24.29 | N/A |
| Revenue | ★ $2,143,782,000.00 | $181,488,000.00 |
| Revenue This Year | $15.26 | $18.41 |
| Revenue Next Year | $8.18 | $18.87 |
| P/E Ratio | $24.58 | ★ N/A |
| Revenue Growth | 15.76 | ★ 53.40 |
| 52 Week Low | $393.53 | $81.74 |
| 52 Week High | $614.11 | $129.90 |
| Indicator | CVCO | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 45.58 |
| Support Level | $550.99 | $179.65 |
| Resistance Level | $608.06 | $192.44 |
| Average True Range (ATR) | 25.63 | 6.57 |
| MACD | 0.89 | -2.06 |
| Stochastic Oscillator | 73.04 | 31.70 |
Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.